Advertisement: Cambridge Network mid banner
4 June, 2020 - 13:02 By Tony Quested

Former CEO returns to Domainex as chair

Domainex chair Eddy Littler

Following the retirement of Tony Brampton, Eddy Littler has been appointed as non-executive chairman of drug discovery services CRO, Domainex Ltd. He was formerly CEO at the company for eight years.

Littler formerly held senior positions with Wellcome Research Laboratories, GSK and Medivir, where he led the team that discovered Olysio which was a major drug for treatment of hepatitis C virus. 

He became CEO of Domainex in May 2008 and developed the business to become one of the UK’s leading drug discovery CROs. In October 2016, he joined ReViral as CEO. 

ReViral is a UK-based biotechnology company developing therapies for respiratory syncytial virus by developing novel first-in-class medicines and in 2018 Littler led a $55 million Series B. 

He became COO in June 2019 as the company moved into Phase 2 development. Littler is also chairman of Neuro-Bio based in Oxford, researching treatments for Alzheimer’s disease.

Domainex retiring chairman Tony Brampton said: “I am delighted that Eddy Littler has agreed to return to Domainex as chairman. I joined the Domainex board as a non-executive director in 2012 and had the privilege of working with Eddy for a number of years.

“His deep understanding of Domainex’s business and extensive drug discovery expertise will be invaluable to the management team led by our CEO, Tom Mander, as we pursue an accelerated growth strategy and maintain our position at the forefront of drug discovery technology providers.”

Littler added: “I am pleased to have returned to Domainex. During my time as CEO I came to understand how much diverse drug discovery is driven by contract research organisations and how it is possible to establish a reputation for high-quality research within the sector. 

“Since my departure, Domainex has moved from strength to strength growing in size and also in its establishment of advanced biological technologies for screening and developing compounds into drugs.”

Newsletter Subscription

Stay informed of the latest news and features